Insider Selling: Natera, Inc. (NASDAQ:NTRA) Director Sells 2,212 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) Director Gail Boxer Marcus sold 2,212 shares of Natera stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $158.53, for a total value of $350,668.36. Following the transaction, the director now directly owns 19,386 shares in the company, valued at $3,073,262.58. The trade was a 10.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Natera Trading Down 3.3 %

NASDAQ:NTRA opened at $146.06 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.01. Natera, Inc. has a one year low of $52.01 and a one year high of $167.79. The company has a market cap of $19.28 billion, a PE ratio of -82.99 and a beta of 1.53. The firm has a 50-day moving average of $127.38 and a 200-day moving average of $115.61.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm had revenue of $439.80 million during the quarter, compared to analyst estimates of $361.43 million. During the same period in the previous year, the company posted ($0.95) EPS. The company’s revenue for the quarter was up 63.9% on a year-over-year basis. As a group, equities research analysts expect that Natera, Inc. will post -1.96 EPS for the current fiscal year.

Wall Street Analyst Weigh In

NTRA has been the topic of a number of recent analyst reports. Canaccord Genuity Group lifted their price objective on Natera from $150.00 to $165.00 and gave the stock a “buy” rating in a research note on Wednesday. Craig Hallum upped their price objective on shares of Natera from $121.00 to $157.00 and gave the company a “buy” rating in a research note on Wednesday. UBS Group decreased their price objective on shares of Natera from $160.00 to $145.00 and set a “buy” rating for the company in a research report on Friday, August 9th. Sanford C. Bernstein upped their price target on shares of Natera from $125.00 to $135.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. Finally, JPMorgan Chase & Co. increased their price target on Natera from $135.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday. One investment analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company. According to data from MarketBeat.com, Natera has an average rating of “Moderate Buy” and an average target price of $137.65.

Hedge Funds Weigh In On Natera

Large investors have recently bought and sold shares of the stock. Wellington Management Group LLP raised its holdings in shares of Natera by 205.4% in the third quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company’s stock valued at $355,493,000 after purchasing an additional 1,883,481 shares during the last quarter. Farallon Capital Management LLC grew its position in Natera by 13.6% in the 2nd quarter. Farallon Capital Management LLC now owns 4,460,557 shares of the medical research company’s stock worth $483,034,000 after purchasing an additional 532,874 shares in the last quarter. First Light Asset Management LLC increased its stake in Natera by 295.9% in the 1st quarter. First Light Asset Management LLC now owns 656,708 shares of the medical research company’s stock valued at $60,063,000 after buying an additional 490,822 shares during the last quarter. AQR Capital Management LLC lifted its position in shares of Natera by 257.6% during the 2nd quarter. AQR Capital Management LLC now owns 651,523 shares of the medical research company’s stock worth $70,553,000 after buying an additional 469,327 shares in the last quarter. Finally, PointState Capital LP boosted its stake in shares of Natera by 112.0% in the 3rd quarter. PointState Capital LP now owns 782,538 shares of the medical research company’s stock worth $99,343,000 after buying an additional 413,468 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.